本報記者(zhe) 王小偉
中(zhong)證(zheng)網訊 獨一味11月25日晚(wan)間發布公(gong)(gong)告,公(gong)(gong)司董事(shi)會于當日審議通(tong)過了《關于變更(geng)公(gong)(gong)司名稱并(bing)修改公(gong)(gong)司章程的議案》,擬將(jiang)公(gong)(gong)司名稱由“甘(gan)肅獨一味生物制(zhi)藥股(gu)份有限公(gong)(gong)司”變更(geng)為“恒康醫(yi)療集團(tuan)股(gu)份有限公(gong)(gong)司”。
公(gong)(gong)(gong)司(si)(si)(si)表示,公(gong)(gong)(gong)司(si)(si)(si)未來將形成中(zhong)藥(yao)、化(hua)(hua)學藥(yao)品(pin)、生物(wu)制(zhi)藥(yao)、醫(yi)療(liao)四大產業(ye)(ye),重(zhong)點拓展(zhan)醫(yi)療(liao)產業(ye)(ye)。獨一(yi)味公(gong)(gong)(gong)司(si)(si)(si)已在2012年成立(li)了(le)(le)全資子公(gong)(gong)(gong)司(si)(si)(si)四川永(yong)道醫(yi)療(liao)投(tou)資管理(li)有(you)限公(gong)(gong)(gong)司(si)(si)(si),先后收購了(le)(le)蓬溪縣健(jian)順王中(zhong)醫(yi)(骨科(ke))醫(yi)院、德陽美(mei)好明天(tian)醫(yi)院、資陽體檢醫(yi)院三(san)家醫(yi)療(liao)機構(gou)及(ji)(ji)成都平安醫(yi)院的(de)(de)腫瘤(liu)業(ye)(ye)務收益權,全面介入醫(yi)療(liao)服務領域(yu),未來公(gong)(gong)(gong)司(si)(si)(si)還將進一(yi)步拓展(zhan)醫(yi)療(liao)領域(yu),加(jia)(jia)大腫瘤(liu)相(xiang)關醫(yi)療(liao)產業(ye)(ye)的(de)(de)收購兼(jian)并及(ji)(ji)建設。為(wei)(wei)此(ci),公(gong)(gong)(gong)司(si)(si)(si)原名稱“甘肅獨一(yi)味生物(wu)制(zhi)藥(yao)股份(fen)有(you)限公(gong)(gong)(gong)司(si)(si)(si)”已經不能涵蓋公(gong)(gong)(gong)司(si)(si)(si)所(suo)經營的(de)(de)行(xing)業(ye)(ye)。為(wei)(wei)更(geng)清晰地傳達公(gong)(gong)(gong)司(si)(si)(si)未來產業(ye)(ye)規劃,加(jia)(jia)大公(gong)(gong)(gong)司(si)(si)(si)的(de)(de)市場(chang)影(ying)響力,確(que)切體現公(gong)(gong)(gong)司(si)(si)(si)戰略發展(zhan)布局,去(qu)除現有(you)名稱的(de)(de)單一(yi)行(xing)業(ye)(ye)概念,突出公(gong)(gong)(gong)司(si)(si)(si)集(ji)團化(hua)(hua)管理(li)模(mo)式,擬將公(gong)(gong)(gong)司(si)(si)(si)名稱變(bian)更(geng)為(wei)(wei)“恒康醫(yi)療(liao)集(ji)團股份(fen)有(you)限公(gong)(gong)(gong)司(si)(si)(si)”。公(gong)(gong)(gong)司(si)(si)(si)營業(ye)(ye)執照其余信(xin)息保持不變(bian)。
今年以來,獨一味在大健康和醫(yi)(yi)療服務產業(ye)(ye)外延(yan)擴張(zhang)不斷取得進(jin)展(zhan)。根(gen)據記(ji)者統(tong)計(ji),公(gong)(gong)司年初至今已經至少(shao)完成(cheng)5 次收(shou)(shou)(shou)購(gou)(gou),分別為1.2 億元(yuan)收(shou)(shou)(shou)購(gou)(gou)成(cheng)都平(ping)安醫(yi)(yi)院腫瘤業(ye)(ye)務85%收(shou)(shou)(shou)益權;4000萬元(yuan)收(shou)(shou)(shou)購(gou)(gou)德陽、資陽醫(yi)(yi)院100%的(de)股權;8000萬元(yuan)收(shou)(shou)(shou)購(gou)(gou)蓬溪健順王(wang)中醫(yi)(yi)(骨(gu)科)醫(yi)(yi)院100%的(de)股權;1180 萬元(yuan)收(shou)(shou)(shou)購(gou)(gou)白(bai)山市三寶堂生物科技有限公(gong)(gong)司100%的(de)股權。由于(yu)公(gong)(gong)司今日公(gong)(gong)告(gao)明確表示公(gong)(gong)司未(wei)來將形(xing)成(cheng)中藥(yao)、化學藥(yao)品(pin)、生物制藥(yao)、醫(yi)(yi)療四大產業(ye)(ye),重點拓展(zhan)醫(yi)(yi)療產業(ye)(ye),業(ye)(ye)內(nei)預計(ji)公(gong)(gong)司未(wei)來在大健康和醫(yi)(yi)療服務產業(ye)(ye)外延(yan)擴張(zhang)還(huan)將繼續。
至于更(geng)(geng)名(ming)對公司(si)是利是弊(bi),業內人士看法(fa)不一。整體來(lai)說,倘若公司(si)品牌已經具有很(hen)大知名(ming)度,更(geng)(geng)名(ming)則面臨極大風險(xian);但另(ling)一方面,對于某些績差(cha)公司(si)來(lai)說,更(geng)(geng)名(ming)往往又能(neng)刺激業務(wu)變更(geng)(geng)的想象預期(qi),從而帶來(lai)二級(ji)市(shi)場的炒作。
此外(wai),公司(si)(si)(si)同日(ri)還發布公告稱,董事會于(yu)當(dang)日(ri)通過議(yi)案,為保證(zheng)公司(si)(si)(si)控(kong)股子(zi)公司(si)(si)(si)四川奇力制(zhi)藥有限(xian)公司(si)(si)(si)生產經營持(chi)續健康地發展(zhan),同意公司(si)(si)(si)以自有資(zi)金向其提供財務資(zi)助不超過6000萬元(yuan),使(shi)用期限(xian)為1年。
中(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)聲明(ming):凡本網(wang)(wang)(wang)注明(ming)“來源:中(zhong)(zhong)國(guo)證(zheng)(zheng)券(quan)報(bao)(bao)·中(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)”的所有作(zuo)(zuo)(zuo)品(pin)(pin),版權(quan)(quan)(quan)均(jun)屬于中(zhong)(zhong)國(guo)證(zheng)(zheng)券(quan)報(bao)(bao)、中(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)。中(zhong)(zhong)國(guo)證(zheng)(zheng)券(quan)報(bao)(bao)·中(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)與(yu)作(zuo)(zuo)(zuo)品(pin)(pin)作(zuo)(zuo)(zuo)者(zhe)(zhe)(zhe)聯合聲明(ming),任(ren)何組織未經(jing)中(zhong)(zhong)國(guo)證(zheng)(zheng)券(quan)報(bao)(bao)、中(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)以及作(zuo)(zuo)(zuo)者(zhe)(zhe)(zhe)書面(mian)授權(quan)(quan)(quan)不得轉(zhuan)載(zai)(zai)(zai)、摘編或(huo)利(li)用其(qi)它方式使用上述作(zuo)(zuo)(zuo)品(pin)(pin)。凡本網(wang)(wang)(wang)注明(ming)來源非中(zhong)(zhong)國(guo)證(zheng)(zheng)券(quan)報(bao)(bao)·中(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)的作(zuo)(zuo)(zuo)品(pin)(pin),均(jun)轉(zhuan)載(zai)(zai)(zai)自其(qi)它媒體,轉(zhuan)載(zai)(zai)(zai)目的在于更好服(fu)務讀(du)者(zhe)(zhe)(zhe)、傳遞信(xin)息之需(xu),并不代表本網(wang)(wang)(wang)贊同(tong)其(qi)觀點,本網(wang)(wang)(wang)亦不對其(qi)真實性(xing)負責,持異(yi)議者(zhe)(zhe)(zhe)應與(yu)原出處單(dan)位主張權(quan)(quan)(quan)利(li)。
特別鏈接:政府部門交易機構證券期貨四所兩司新聞發布平臺友情鏈接版權聲明
關于報社關于本站廣告發布免責條款
中國證券報社版權所有,未經書面授權不得復制或建立鏡像 經營許可證編號:京B2-20180749 京公網安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved
中國證券報社版權(quan)所有,未(wei)經(jing)書(shu)面(mian)授權(quan)不得復(fu)制或(huo)建立(li)鏡像
經營(ying)許可(ke)證編號:京(jing)(jing)B2-20180749 京(jing)(jing)公網安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved